Abbott Laboratories vs Bristol Myers Squibb (ABT vs BMY)
Side by side from their SEC filings: revenue, margins, growth, returns and valuation, plus short interest, insider activity and institutional ownership.
Bristol Myers Squibb is the larger company by revenue ($48.2B vs $44.3B). Abbott Laboratories carries the larger market value ($163.6B vs $117.6B). Abbott Laboratories grew revenue faster in its latest fiscal year (+5.7% vs -0.2%). Bristol Myers Squibb trades at the lower trailing P/E (16.1x vs 26.3x).
About Abbott Laboratories
Abbott Laboratories develops, manufactures, and sells a wide range of healthcare products globally. Its main business segments include established pharmaceutical products sold primarily outside the U.S., diagnostic systems and tests used in various healthcare settings, nutritional products for infants and adults, and medical devices for cardiovascular, diabetes care, and neuromodulation treatments. The company serves customers such as healthcare providers, government agencies, consumers, and distributors worldwide.
About Bristol Myers Squibb
Bristol Myers Squibb is a biopharmaceutical company that discovers, develops, manufactures, markets, and sells innovative medicines for serious diseases. Its main products include biologics, small molecule drugs, CAR-T cell therapies, and radiopharmaceuticals used to treat conditions such as cancer, autoimmune diseases, cardiovascular and neurological disorders. The company serves patients worldwide through wholesalers, distributors, specialty pharmacies, hospitals, clinics, and government agencies.
Head to head (ABT FY2025 vs BMY FY2025)
| Metric | ABTFY2025 | BMYFY2025 |
|---|---|---|
| Revenue | $44.33B | $48.19B |
| Revenue growth (YoY) | 5.7% | -0.2% |
| Gross margin | 56.4% | 71.1% |
| Operating margin | 18.2% | — |
| Net margin | 14.7% | 14.6% |
| Net income | $6.52B | $7.05B |
| Diluted EPS | $3.72 | $3.46 |
| FCF margin | 16.7% | 26.7% |
| ROE | 12.4% | 38.1% |
| Debt / equity | 0.2× | 2.3× |
| Market cap | $163.61B | $117.58B |
| P/E (TTM) | 26.3× | 16.1× |
Fundamentals are from each company’s SEC filings (ABT FY2025, BMY FY2025). P/E and market cap are derived from recent market prices and update daily.
Five-year trend (as reported)
| Revenue | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| ABT | $43.08B | $43.65B | $40.11B | $41.95B | $44.33B |
| BMY | $46.38B | $46.16B | $45.01B | $48.30B | $48.19B |
Peer standing
Where each company ranks among the 198 pharmaceutical companies, on the same scale. Each figure is ranked only against peers that report it. Percentiles describe position in the distribution, not a rating.
| Metric | ABT | BMY |
|---|---|---|
| Gross margin | 56.4%39th percentile of 68 | 71.1%57th percentile of 68 |
| Net margin | 14.7%77th percentile of 121 | 14.6%76th percentile of 121 |
| FCF margin | 16.7%69th percentile of 109 | 26.7%86th percentile of 109 |
| Revenue growth (YoY) | +5.7%41st percentile of 186 | -0.2%34th percentile of 186 |
| ROE | 12.4%78th percentile of 167 | 38.1%93rd percentile of 167 |
| P/E (TTM) | 26.3×70th percentile of 61 | 16.1×48th percentile of 61 |
| Debt / equity | 0.19×31st percentile of 65 | 2.32×91st percentile of 65 |
| Short interest (days to cover) | 1.48d10th percentile of 197 | 2.47d22nd percentile of 197 |
Short interest
| FINRA settlement data | ABT | BMY |
|---|---|---|
| Shares sold short | 23.4M | 40.5M |
| Change vs prior settlement | +6.4% | +2.4% |
| Days to cover | 1.48 | 2.47 |
| As of settlement | 2026-06-30 | 2026-06-30 |
Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data; republishing or redistributing it is not permitted. Not presented as a percentage of float. No FINRA endorsement of this product is implied.
Insider activity (last 90 days)
| Form 4 open-market activity | ABT | BMY |
|---|---|---|
| Buys | 3 ($1.3M) | — |
| Sells | 0 | — |
Open-market purchases and sales reported on SEC Form 4 (grants, exercises and tax withholding excluded). For context, about 16% of covered companies saw any open-market insider buy in a 90-day window.
Held by the same investors
9 tracked 13F managers hold both Abbott Laboratories and Bristol Myers Squibb as of their latest quarterly filings: AQR Capital Management, Bridgewater Associates, Citadel Advisors, D. E. Shaw, Dodge & Cox, Gotham Asset Management, Millennium Management, Renaissance Technologies, Two Sigma Investments. See which superinvestors hold your own portfolio with the smart money checker.
Go deeper
ABBV vs ABTABT vs JNJABT vs LLYABT vs MRKABT vs PFEABT vs VRTXAll pharmaceutical stocks →All comparisons →
Track ABT and BMY
Get an alert when either company files something material, see which superinvestors own them, and ask their filings a question with cited answers.
Start monitoring freeIncludes one free filing-grounded research answer. Or check your whole portfolio, no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filings before relying on them. Comparisons are descriptive (higher or lower on a reported figure), not a rating or a recommendation. Informational only. Not investment advice.